コンテンツへスキップ
Merck

SAB4500795

Sigma-Aldrich

抗ERCC1抗体 ウサギ宿主抗体

affinity isolated antibody

別名:

cofs4, ercc1, excision repair cross-complementing 1, excision repair cross-complementing 1 isoform 1, excision repair cross-complementing 1 isofrom 2

ログイン組織・契約価格を表示する


About This Item

MDL番号:
UNSPSCコード:
12352203
NACRES:
NA.43

由来生物

rabbit

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

フォーム

buffered aqueous solution

分子量

antigen 32 kDa

交差性

mouse, human

濃度

~1 mg/mL

テクニック

ELISA: 1:5000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

NCBIアクセッション番号

UniProtアクセッション番号

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... ERCC1(2067)

詳細

Anti-ERCC1 Antibody detects endogenous levels of total ERCC1 protein.

免疫原

The antiserum was produced against synthesized peptide derived from human ERCC1.

Immunogen Range: 141-190

特徴および利点

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

物理的形状

ウサギIgGのPBS溶液(Mg2+およびCa2+を含まず)、pH 7.4、150 mM NaCl、0.02% アジ化ナトリウム、50% グリセロール

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

WGK

nwg

引火点(°F)

Not applicable

引火点(℃)

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Virgílio Souza E Silva et al.
Diagnostics (Basel, Switzerland), 11(3) (2021-04-04)
The discovery of predictive biomarkers in metastatic colorectal cancer (mCRC) is essential to improve clinical outcomes. Recent data suggest a potential role of circulating tumor cells (CTCs) as prognostic indicators. We conducted a follow-on analysis from a prospective study of
Thomas R Muley et al.
Anticancer research, 34(7), 3707-3713 (2014-07-02)
Expression of excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) was suggested to be of predictive value for selecting patients with clinical benefit from platinum-based chemotherapy. In order to validate the prognostic and predictive value of ERCC1, we
Ann Marie Egloff et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5041-5051 (2014-08-12)
Treatment with cisplatin or cetuximab combined with radiotherapy each yield superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) compared with radiotherapy alone. Eastern Cooperative Oncology Group Trial E3303 evaluated the triple combination. Patients with stage IV
Takashi Ohta et al.
Journal of neuropathology and experimental neurology, 73(10), 908-915 (2014-09-06)
Gemistocytic astrocytoma (World Health Organization grade II) is a rare variant of diffuse astrocytoma that is characterized by the presence of neoplastic gemistocytes and has a significantly less favorable prognosis. Other than frequent TP53 mutations (>80%), little is known about

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)